iglucose to Commercially Launch During Second Quarter 2012

DELRAY BEACH, Fla., April 11, 2012 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America’s homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose® mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com. PositiveID expects to commercially launch iglucose during the second quarter of 2012.

PositiveID’s FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.

“As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management,” stated William J. Caragol, Chairman and CEO of PositiveID. “Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers.”

The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan®, Abbott FreeStyle®, Bayer Contour ®, and Nipro Diagnostic™ True™ monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America’s homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID’s future expectations, including the likelihood that PositiveID expects to commercially launch iglucose during the second quarter of 2012; the likelihood that iglucose makes it possible to improve care in a cost-effective manner; the likelihood that iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition; the likelihood that those who order will be given priority status while the Company initially rolls-out iglucose through pilot programs with health insurers and home-healthcare providers; the likelihood that the Company is continually adding to its list of supported glucose meters; and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include PositiveID’s ability to successfully commercialize its diabetes management products including iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 28, 2012, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com

Source: Globe Newswire (April 11, 2012 – 8:30 AM EDT)